31st Mar 2008 17:00
AstraZeneca PLC31 March 2008 Transaction by Persons Discharging Managerial ResponsibilitiesDisclosure Rules DR 3.1.4R We hereby inform you that on 28 March 2008 the following Directors ofAstraZeneca PLC were each granted an award under the terms of the AstraZenecaPerformance Share Plan over the Company's USD0.25 Ordinary Shares. Target Award Total interest Percentage number price Normal in shares of shares of shares per vesting after this in issueName of Director awarded share date award D R Brennan 161,546 1882p 28 March 2011 See below See below S Lowth 58,448 1882p 28 March 2011 76,192 0.005% J S Patterson 57,385 1882p 28 March 2011 197,107 0.014% The AstraZeneca Performance Share Plan was approved by shareholders at theCompany's AGM in 2005. Awards made under the Plan may not generally vest beforethe third anniversary of the relevant date of grant nor unless the specifiedperformance target(s) have been met at the end of the three year period which,for this award, is 1 January 2008 to 31 December 2010. The performance target that applies to this award is the Company's TotalShareholder Return ("TSR") compared to the TSR of a selected peer group of 12other pharmaceutical companies. The actual number of shares to which aparticipant may become unconditionally entitled will depend on the extent towhich the performance target(s) have been met. A summary of the Plan, includinga more detailed explanation of the performance target(s), can be found in theAstraZeneca Annual Report and Form 20-F Information 2007 which is available onthe Company's website www.astrazeneca.com. Mr Brennan has interests in the Company's Ordinary Shares and AmericanDepositary Shares (ADSs). One ADS equals one Ordinary Share. In total, MrBrennan now has an interest in 395,974 Ordinary Shares and 111,273 ADSs, whichtogether represent approximately 0.035% of the number of shares currently inissue. G H R MuskerCompany Secretary31 March 2008 This information is provided by RNS The company news service from the London Stock ExchangeRelated Shares:
Astrazeneca